Search - tctmd.com

Displaying 941 - 960 of 1240

Sort: Relevancy | Date

News Daily News

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

Michael O'Riordan

April 02, 2016

News Daily News

ACC actualiza las recomendaciones para bajar el colesterol LBD, abriendo un espacio para el uso de Ezetimibe y de los inhibidores de PCSK9

Michael O'Riordan

April 02, 2016

News Daily News

美国指南更新，将接受 DES 的稳定患者的 DAPT 持续时间从 12 个月下调为 6 个月

Yael L. Maxwell

March 30, 2016

News Daily News

Updated US Guidelines Lower DAPT Duration From 12 to 6 Months in Stable Patients Receiving DES

Yael L. Maxwell

March 30, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2016

Shelley Wood

March 30, 2016

News Daily News

Las Últimas Directrices Norteamericanas Reducen la Duración del Tratamiento Antiplaquetario Doble de 12 a 6 Meses en Pacientes Estables que Reciben un SLF

Yael L. Maxwell

March 30, 2016

News Daily News

Crushed Prasugrel Pills Beat Whole Tablets for Controlling Platelets During Primary PCI

Caitlin E. Cox

March 28, 2016

News Daily News

Un Nuevo Análisis del COGENT Avala el Uso de PPI en Pacientes con Dosis Bajas de Aspirina

Caitlin E. Cox

March 23, 2016

News Daily News

New Analysis of COGENT Supports PPI Use in Patients on Low-Dose Aspirin

Caitlin E. Cox

March 23, 2016

News Daily News

COGENT 新分析支持对低剂量阿司匹林患者使用 PPI

Caitlin E. Cox

March 23, 2016

News Daily News

Newer-Generation DES With Abbreviated DAPT Bests BMS in Patients at High Risk for Bleeding

L.A. McKeown

March 08, 2016

News Daily News

双倍剂量的氯吡格雷可以解决“吸烟者悖论”：GRAVITAS 分析

Michael O'Riordan

February 28, 2016

Presentation

Influence of Smoking on the Antiplatelet Effect of Clopidogrel Differs by Dose: GRAVITAS

Presenter: Grant Reed

February 28, 2016

News Daily News

Análisis del Ensayo GRAVITAS: La ‘Paradoja del Fumador’ Desaparece con Dosis Dobles de Clopidogrel

Michael O'Riordan

February 28, 2016

News Daily News

‘Smoker’s Paradox’ Eliminated With Double Dose of Clopidogrel: GRAVITAS Analysis

Michael O'Riordan

February 28, 2016

News Daily News

Trial Affirms Aspirin Is Safe to Continue Before Coronary Artery Surgery

Todd Neale

February 25, 2016

News Industry News

Meta-Analysis of AGGRASTAT® (Tirofiban HCl) Presented at CRT 2016 Conference

February 22, 2016

News Daily News

研究认为有数据支持针对患者风险而非 LDL 胆固醇目标进行治疗

Michael O'Riordan

February 15, 2016

News Daily News

Según un Informe los Datos Avalan Tratar el Riesgo de los Pacientes No las Dianas de Colesterol LBD

Michael O'Riordan

February 15, 2016

News Daily News

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

Michael O'Riordan

February 15, 2016

Advertisement

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

ACC actualiza las recomendaciones para bajar el colesterol LBD, abriendo un espacio para el uso de Ezetimibe y de los inhibidores de PCSK9

美国指南更新，将接受 DES 的稳定患者的 DAPT 持续时间从 12 个月下调为 6 个月

Updated US Guidelines Lower DAPT Duration From 12 to 6 Months in Stable Patients Receiving DES

TCTMD’s Top 10 Most Popular Stories for March 2016

Las Últimas Directrices Norteamericanas Reducen la Duración del Tratamiento Antiplaquetario Doble de 12 a 6 Meses en Pacientes Estables que Reciben un SLF

Crushed Prasugrel Pills Beat Whole Tablets for Controlling Platelets During Primary PCI

Un Nuevo Análisis del COGENT Avala el Uso de PPI en Pacientes con Dosis Bajas de Aspirina

New Analysis of COGENT Supports PPI Use in Patients on Low-Dose Aspirin

COGENT 新分析支持对低剂量阿司匹林患者使用 PPI

Newer-Generation DES With Abbreviated DAPT Bests BMS in Patients at High Risk for Bleeding

双倍剂量的氯吡格雷可以解决“吸烟者悖论”：GRAVITAS 分析

Influence of Smoking on the Antiplatelet Effect of Clopidogrel Differs by Dose: GRAVITAS

Análisis del Ensayo GRAVITAS: La ‘Paradoja del Fumador’ Desaparece con Dosis Dobles de Clopidogrel

‘Smoker’s Paradox’ Eliminated With Double Dose of Clopidogrel: GRAVITAS Analysis

Trial Affirms Aspirin Is Safe to Continue Before Coronary Artery Surgery

Meta-Analysis of AGGRASTAT® (Tirofiban HCl) Presented at CRT 2016 Conference

研究认为有数据支持针对患者风险而非 LDL 胆固醇目标进行治疗

Según un Informe los Datos Avalan Tratar el Riesgo de los Pacientes No las Dianas de Colesterol LBD

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content